These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

271 related items for PubMed ID: 24652496

  • 1. Better neutralization of herpes simplex virus type 1 (HSV-1) than HSV-2 by antibody from recipients of GlaxoSmithKline HSV-2 glycoprotein D2 subunit vaccine.
    Awasthi S, Belshe RB, Friedman HM.
    J Infect Dis; 2014 Aug 15; 210(4):571-5. PubMed ID: 24652496
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Vaccine-induced antibodies to herpes simplex virus glycoprotein D epitopes involved in virus entry and cell-to-cell spread correlate with protection against genital disease in guinea pigs.
    Hook LM, Cairns TM, Awasthi S, Brooks BD, Ditto NT, Eisenberg RJ, Cohen GH, Friedman HM.
    PLoS Pathog; 2018 May 15; 14(5):e1007095. PubMed ID: 29791513
    [Abstract] [Full Text] [Related]

  • 4. Serum and Cervicovaginal Fluid Antibody Profiling in Herpes Simplex Virus-Seronegative Recipients of the HSV529 Vaccine.
    Wang K, Dropulic L, Bozekowski J, Pietz HL, Jegaskanda S, Dowdell K, Vogel JS, Garabedian D, Oestreich M, Nguyen H, Ali MA, Lumbard K, Hunsberger S, Reifert J, Haynes WA, Sawyer JR, Shon JC, Daugherty PS, Cohen JI.
    J Infect Dis; 2021 Nov 16; 224(9):1509-1519. PubMed ID: 33718970
    [Abstract] [Full Text] [Related]

  • 5. A Dual-Modality Herpes Simplex Virus 2 Vaccine for Preventing Genital Herpes by Using Glycoprotein C and D Subunit Antigens To Induce Potent Antibody Responses and Adenovirus Vectors Containing Capsid and Tegument Proteins as T Cell Immunogens.
    Awasthi S, Mahairas GG, Shaw CE, Huang ML, Koelle DM, Posavad C, Corey L, Friedman HM.
    J Virol; 2015 Aug 16; 89(16):8497-509. PubMed ID: 26041292
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Protection from herpes simplex virus (HSV)-2 infection with replication-defective HSV-2 or glycoprotein D2 vaccines in HSV-1-seropositive and HSV-1-seronegative guinea pigs.
    Hoshino Y, Pesnicak L, Dowdell KC, Burbelo PD, Knipe DM, Straus SE, Cohen JI.
    J Infect Dis; 2009 Oct 01; 200(7):1088-95. PubMed ID: 19702506
    [Abstract] [Full Text] [Related]

  • 8. Improving immunogenicity and efficacy of vaccines for genital herpes containing herpes simplex virus glycoprotein D.
    Awasthi S, Shaw C, Friedman H.
    Expert Rev Vaccines; 2014 Dec 01; 13(12):1475-88. PubMed ID: 25138572
    [Abstract] [Full Text] [Related]

  • 9. Protection provided by a herpes simplex virus 2 (HSV-2) glycoprotein C and D subunit antigen vaccine against genital HSV-2 infection in HSV-1-seropositive guinea pigs.
    Awasthi S, Balliet JW, Flynn JA, Lubinski JM, Shaw CE, DiStefano DJ, Cai M, Brown M, Smith JF, Kowalski R, Swoyer R, Galli J, Copeland V, Rios S, Davidson RC, Salnikova M, Kingsley S, Bryan J, Casimiro DR, Friedman HM.
    J Virol; 2014 Feb 01; 88(4):2000-10. PubMed ID: 24284325
    [Abstract] [Full Text] [Related]

  • 10. A Randomized, Double-Blinded, Placebo-Controlled, Phase 1 Study of a Replication-Defective Herpes Simplex Virus (HSV) Type 2 Vaccine, HSV529, in Adults With or Without HSV Infection.
    Dropulic LK, Oestreich MC, Pietz HL, Laing KJ, Hunsberger S, Lumbard K, Garabedian D, Turk SP, Chen A, Hornung RL, Seshadri C, Smith MT, Hosken NA, Phogat S, Chang LJ, Koelle DM, Wang K, Cohen JI.
    J Infect Dis; 2019 Aug 09; 220(6):990-1000. PubMed ID: 31058977
    [Abstract] [Full Text] [Related]

  • 11. Global sensing of the antigenic structure of herpes simplex virus gD using high-throughput array-based SPR imaging.
    Cairns TM, Ditto NT, Lou H, Brooks BD, Atanasiu D, Eisenberg RJ, Cohen GH.
    PLoS Pathog; 2017 Jun 09; 13(6):e1006430. PubMed ID: 28614387
    [Abstract] [Full Text] [Related]

  • 12. Cervical antibody responses to a herpes simplex virus type 2 glycoprotein subunit vaccine.
    Ashley RL, Crisostomo FM, Doss M, Sekulovich RE, Burke RL, Shaughnessy M, Corey L, Polissar NL, Langenberg AG.
    J Infect Dis; 1998 Jul 09; 178(1):1-7. PubMed ID: 9652416
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Neutralizing Antibody Kinetics and Immune Protection Against Herpes Simplex Virus 1 Genital Disease in Vaccinated Women.
    Belshe RB, Blevins TP, Yu Y, Nethington AE, Bellamy A, Bryant C, Morrison LA.
    J Infect Dis; 2023 Feb 14; 227(4):522-527. PubMed ID: 35199165
    [Abstract] [Full Text] [Related]

  • 15. Recombinant glycoprotein vaccine for the prevention of genital HSV-2 infection: two randomized controlled trials. Chiron HSV Vaccine Study Group.
    Corey L, Langenberg AG, Ashley R, Sekulovich RE, Izu AE, Douglas JM, Handsfield HH, Warren T, Marr L, Tyring S, DiCarlo R, Adimora AA, Leone P, Dekker CL, Burke RL, Leong WP, Straus SE.
    JAMA; 1999 Jul 28; 282(4):331-40. PubMed ID: 10432030
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Efficacy of the Herpes Simplex Virus 2 (HSV-2) Glycoprotein D/AS04 Vaccine against Genital HSV-2 and HSV-1 Infection and Disease in the Cotton Rat Sigmodon hispidus Model.
    Boukhvalova M, McKay J, Mbaye A, Sanford-Crane H, Blanco JC, Huber A, Herold BC.
    J Virol; 2015 Oct 28; 89(19):9825-40. PubMed ID: 26178984
    [Abstract] [Full Text] [Related]

  • 18. [Construction and Immunogenicity Analysis of Herpes Simplex Virus Type 2 Glycoprotein D Recombinant Adenovirus Vaccine].
    Liu W, Zhao D, Wang Z, Li Y, Wang H, Wang H.
    Bing Du Xue Bao; 2016 May 28; 32(3):267-72. PubMed ID: 29962197
    [Abstract] [Full Text] [Related]

  • 19. Correlation between herpes simplex virus neutralizing antibody titers determined by ELVIS cell and traditional plaque reduction assays.
    Blevins TP, Yu Y, Belshe RB, Bellamy AR, Morrison LA.
    PLoS One; 2019 May 28; 14(4):e0214467. PubMed ID: 30946751
    [Abstract] [Full Text] [Related]

  • 20. Safety and immunogenicity of a glycoprotein D genital herpes vaccine in healthy girls 10-17 years of age: results from a randomised, controlled, double-blind trial.
    HSV-040 Study Group, Abu-Elyazeed RR, Heineman T, Dubin G, Fourneau M, Leroux-Roels I, Leroux-Roels G, Richardus JH, Ostergaard L, Diez-Domingo J, Poder A, Van Damme P, Romanowski B, Blatter M, Silfverdal SA, Berglund J, Josefsson A, Cunningham AL, Flodmark CE, Tragiannidis A, Dobson S, Olafsson J, Puig-Barbera J, Mendez M, Barton S, Bernstein D, Mares J, Ratner P.
    Vaccine; 2013 Dec 09; 31(51):6136-43. PubMed ID: 23850416
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.